Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Endologix, Inc is a medical instruments & supplies business based in the US. Endologix shares (ELGX) are listed on the NASDAQ and all prices are listed in US Dollars. Endologix employs 488 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.01 - $0.22|
|50-day moving average||$0.03|
|200-day moving average||$0.47|
|Wall St. target price||$0.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$136.3 million|
|Gross profit TTM||$91.1 million|
|Return on assets TTM||-9.82%|
|Return on equity TTM||0%|
|Market capitalisation||$4.2 million|
TTM: trailing 12 months
There are currently 343,574 Endologix shares held short by investors – that's known as Endologix's "short interest". This figure is 45.3% up from 236,448 last month.
There are a few different ways that this level of interest in shorting Endologix shares can be evaluated.
Endologix's "short interest ratio" (SIR) is the quantity of Endologix shares currently shorted divided by the average quantity of Endologix shares traded daily (recently around 377553.84615385). Endologix's SIR currently stands at 0.91. In other words for every 100,000 Endologix shares traded daily on the market, roughly 910 shares are currently held short.
However Endologix's short interest can also be evaluated against the total number of Endologix shares, or, against the total number of tradable Endologix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Endologix's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Endologix shares in existence, roughly 20 shares are currently held short) or 0.0202% of the tradable shares (for every 100,000 tradable Endologix shares, roughly 20 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Endologix.
Find out more about how you can short Endologix stock.
We're not expecting Endologix to pay a dividend over the next 12 months.
Endologix's shares were split on a 1:10 basis on 5 March 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Endologix shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Endologix shares which in turn could have impacted Endologix's share price.
Over the last 12 months, Endologix's shares have ranged in value from as little as $0.01 up to $0.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Endologix's is 0.735. This would suggest that Endologix's shares are less volatile than average (for this exchange).
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.